Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. is dated February 13, 2024. The document serves as a notice of an Extraordinary General Meeting of Shareholders scheduled for March 20, 2024, at the company's offices in Tel Aviv, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a corporate governance notice and does not contain financial statements or performance data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The primary corporate action proposed is an increase in the Company's authorized share capital.
Guidance, Outlook, and Management Commentary
The Board of Directors recommends that shareholders vote FOR the proposal to increase authorized share capital. The filing notes that the Company is currently unaware of any other matters that may be raised at the meeting. Shareholders wishing to express a position on the agenda item may submit a written statement by March 10, 2024.
Key Facts for Investor Verification
- Meeting Date: March 20, 2024, at 3:00 p.m. Israel time.
- Record Date: February 19, 2024 (holders of record of ADSs are entitled to vote).
- Primary Agenda: Approval of an increase in the Company's authorized share capital.
- Board Recommendation: Vote FOR the proposal.
- Quorum Requirement: If a quorum is not present within half an hour, the meeting will be adjourned to the next business day.